Key result
Heparanase drives septic cardiomyopathy via inflammation, microvascular dysfunction, mitochondrial injury, and fibrosis.
Why the study?
Septic cardiomyopathy causes high mortality, and heparanase has been hypothesized to play an important role in its pathogenesis through shared mechanisms like microcirculation disturbance, mitochondrial dysfunction, and fibrosis.
Heparanase acts as a key mediator in septic cardiomyopathy pathophysiology and may represent a novel target for diagnosis and therapeutic intervention.
Answers are grounded in this paper and cite their sources.
Heparanase may be a novel target in septic cardiomyopathy; leaves open diagnostic or therapeutic utility pending clinical validation.
Septic cardiomyopathy (SCM) is a severe complication caused by sepsis, resulting in a high mortality rate. The current understanding of the pathogenic mechanism of SCM primarily involves endocardial injury, microcirculation disturbance, mitochondrial dysfunction and fibrosis. Heparanase (HPA), an endo-β-D-glucuronidase, has been implicated in inflammation, immune response, coagulation promotion, microcirculation disturbance, mitochondrial dysfunction and fibrosis. Therefore, it was hypothesized that HPA may play an important role in the pathogenesis of SCM. The present study provides a summary of various pathophysiological changes and mechanisms behind the involvement of HPA in SCM. It also presents a novel perspective on the pathogenic mechanism, diagnosis and treatment of SCM.
No takes yet. Share an insight, caveat, or question.
Chen et al. (2024) conducted a review in Septic cardiomyopathy. Heparanase was evaluated. Heparanase is implicated in the pathogenesis of septic cardiomyopathy by promoting inflammation, microcirculation disturbance, mitochondrial dysfunction, and fibrosis.
Synapse has enriched 10 related papers. Consider them for comparative context: